These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30687065)

  • 1. Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia.
    Pan E; Hsieh E; Piatek C
    Case Rep Oncol; 2018; 11(3):880-882. PubMed ID: 30687065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of oxaliplatin-induced immune-mediated thrombocytopenia.
    Suh SE; Jang MJ; Chong SY; Aster RH; Curtis BR; Oh D
    Blood Res; 2014 Mar; 49(1):61-4. PubMed ID: 24724069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report.
    Woo HS; Lee KH; Yoon PH; Kim SJ; Park I; Kim YS; Ahn HK; Hong J; Shin DB; Sym SJ
    Cancer Res Treat; 2015 Oct; 47(4):949-53. PubMed ID: 25544580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-induced acute thrombocytopenia.
    Erdem GU; Dogan M; Demirci NS; Zengin N
    J Cancer Res Ther; 2016; 12(2):509-14. PubMed ID: 27461601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Three cases of fatal thrombocytopenia after oxaliplatin-based chemotherapy].
    Osumi H; Shinozaki E; Kumekawa Y; Ogura M; Ozaka M; Suenaga M; Matsusaka S; Chin K; Mizunuma N; Yokoyama M
    Gan To Kagaku Ryoho; 2013 Nov; 40(11):1557-60. PubMed ID: 24231715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.
    Vyskocil J; Tucek S; Kiss I; Fedorova L; Nevrlka J; Zdrazilova-Dubska L
    Int Immunopharmacol; 2019 Sep; 74():105728. PubMed ID: 31288153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
    James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
    Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-induced immune mediated thrombocytopenia.
    Beg MS; Komrokji RS; Ahmed K; Safa MM
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia.
    Curtis SA; Curtis BR; Lee AI; Hendrickson JE; Lacy J; Podoltsev NA
    Hematology; 2018 Aug; 23(7):429-432. PubMed ID: 29281948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms.
    Ghazanfar H; Nawaz I; Ali N
    Cureus; 2020 Aug; 12(8):e9929. PubMed ID: 32968590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.
    Forcello NP; Khubchandani S; Patel SJ; Brahaj D
    J Oncol Pharm Pract; 2015 Apr; 21(2):148-56. PubMed ID: 24500808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia.
    Yamada S; Yazawa M; Yamamoto M; Koitabashi K; Ichikawa D; Koike J; Shibagaki Y
    CEN Case Rep; 2019 Aug; 8(3):188-193. PubMed ID: 30827015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-induced acute thrombocytopenia: a case report and review of the literature.
    Suzuki K; Oda H; Sugawara Y; Masuya M; Nakase K; Fujioka M; Imai H; Katayama N
    Intern Med; 2013; 52(5):611-5. PubMed ID: 23448774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis.
    Koutras AK; Makatsoris T; Paliogianni F; Kopsida G; Onyenadum A; Gogos CA; Mouzaki A; Kalofonos HP
    Oncology; 2004; 67(2):179-82. PubMed ID: 15539924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute drop of platelets in metastatic colon cancer.
    Ahmed AT; Gupta S
    Clin Case Rep; 2017 Nov; 5(11):1862-1864. PubMed ID: 29152287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
    Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytopenia in cancer patients.
    Liebman HA
    Thromb Res; 2014 May; 133 Suppl 2():S63-9. PubMed ID: 24862148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin-induced renal tubular vacuolization.
    Joybari AY; Sarbaz S; Azadeh P; Mirafsharieh SA; Rahbari A; Farasatinasab M; Mokhtari M
    Ann Pharmacother; 2014 Jun; 48(6):796-800. PubMed ID: 24615628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy.
    Tam EL; Draksharam PL; Park JA; Sidhu GS
    Case Rep Oncol Med; 2019; 2019():4314797. PubMed ID: 31781443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment continuation with a single mild partial splenic embolization for thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced colon cancer.
    Heianna J; Muto O; Miyauchi T; Endo W; Togashi A; Azama K; Murayama S
    Indian J Gastroenterol; 2016 May; 35(3):245-7. PubMed ID: 27230031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.